ARVN - Arvinas, Inc. Forward P/S Multiple

Corporate company logo of Arvinas, Inc. (ARVN)

The forward P/S history in the GURU.Markets terminal displays a chart of the metric that helps assess the potential of Arvinas, Inc. (ARVN) and its PROTAC technology for destroying cancer proteins. Value growth is based on patents for licensing developments to pharma behemoths, while stability is ensured by climate-controlled reagent supply chains. Meanwhile, the 1.60 mark captures this indicator, allowing for an analysis of the ratio of the business's market price to its expected annual revenue.

ARVN arvinas.com: Market Cap to Projected Revenue in the range 07/04/2022 - 11/15/2026

Analytical breakdowns for Arvinas, Inc.

- stock price and consensus target price:
Stock Quotes Arvinas Corp|ARVN - Price Target Chart
- market capitalization statistics:
Market Capitalization Arvinas Corp|ARVN - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share Arvinas|ARVN - Accounting Capitalization|Market Capitalization to Book Value Ratio arvinas.com|ARVN - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Arvinas, Inc.|ARVN - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Arvinas|ARVN - Aggregate Debt Obligations|Debts to Book Capitalization Arvinas Corp|ARVN - Long-Term Debt Volume|Company Short-Term Debt Arvinas|Quick Ratio arvinas.com
- business earnings and investment ratios data:
ARVN - Net Income|Future Profit Arvinas, Inc.|ARVN - Business Payback Period|Forward P/E Multiple Arvinas Bio|ARVN - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arvinas Inc|ARVN - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Arvinas|ARVN - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months arvinas.com|ARVN - Earnings per share growth this year|Earnings growth forecast for next year Arvinas, Inc.
- sales and revenue indicators:
ARVN - Company Sales|Projected Sales Volume Arvinas Inc|ARVN - P/S Multiple|Price-to-Projected Revenue Ratio Arvinas Corp|ARVN - Sales Growth YoY (Last 12 Months)
Summary company analysis:Arvinas Bio ARVN
Original product of arvinas.com

For Arvinas, Inc. (ARVN), which is developing PROTAC technology, the company's forward P/S ratio reflects market expectations for the commercialization of protein degraders. This indicator compares current market capitalization with projected revenue to determine the premium for potential sales growth. The calculation is based on the ratio of market value to expected revenue, accounting for royalties from pharmaceutical partners. An increase in this metric signals investor optimism but necessitates an analysis of whether the asset's valuation is justified.